[Corrections] Correction to Lancet Oncol 2021; 22: 74–84

Toi M, Imoto S, Ishida T, et al. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2021; 22: 74–84—In this Article, the first column of the tenth row in table 2 should have read Bone. This correction has been made to the online version as of March 27, 2023.